TSE:4503Pharmaceuticals
A Look At Astellas Pharma (TSE:4503) Valuation As New Oncology Data Approaches ASCO 2026
Astellas Pharma (TSE:4503) is back in focus after announcing a broad slate of oncology presentations for the 2026 ASCO meeting, including long term data on enfortumab vedotin combinations and updated prostate cancer outcomes.
See our latest analysis for Astellas Pharma.
The recent ASCO announcement comes after a mixed year in the market, with the share price at ¥2,317, a 1-year total shareholder return of 76.57% and a 5-year total shareholder return of 67.14%. However, the 30-day share price...